Agenus (AGEN) Non Operating Income (2010 - 2026)
Agenus (AGEN) posted quarterly Non Operating Income of -$208000.0 for Q1 2026, up 21.21% year-over-year from -$171600.0 in Q1 2025, and up 99.42% quarter-over-quarter from -$35.7 million in Q4 2025.
Analysis
Agenus (AGEN) Non Operating Income (2010 - 2026) Analysis & Trends
Agenus' Non Operating Income history runs 17 years deep, the most recent figure standing at -$208000.0 for Q1 2026.
- In Q1 2026, Non Operating Income rose 21.21% year-over-year to -$208000.0; the TTM figure through Mar 2026 stood at -$55.2 million (up 71.15% YoY), while the FY2025 annual figure was -$55.3 million, up 53.01% from the prior year.
- Non Operating Income for Q1 2026 stood at -$208000.0, up from -$35.7 million in the prior quarter.
- The five-year high for Non Operating Income was $9.1 million in Q2 2022, with the low at -$123.7 million in Q4 2024.
- The 5-year median for Non Operating Income is -$17.3 million (2022), against an average of -$24.5 million.
- The sharpest annual moves came in 2022 and 2024: Non Operating Income soared 1084.89% in 2022, then slumped 73765.0% in 2024.
- Agenus' Non Operating Income stood at -$17.3 million in 2022, then plunged by 466.6% to -$98.2 million in 2023, then decreased by 25.99% to -$123.7 million in 2024, then surged by 71.14% to -$35.7 million in 2025, then jumped by 99.42% to -$208000.0 in 2026.
- Business Quant data shows AGEN's Non Operating Income at -$208000.0 in Q1 2026, -$35.7 million in Q4 2025, and -$19.3 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -139.24 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | -53.64 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | -51.63 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | - |
| 10 | Agenus | 344.35 Mn | 344.35 Mn | 34.52 Mn | 856,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 856,000.00 |
| Mar 31, 2026 | -208,000.00 |
| Dec 31, 2025 | 17.35 Mn |
| Sep 30, 2025 | -19.30 Mn |
| Jun 30, 2025 | -12,000.00 |
| Mar 31, 2025 | -264,000.00 |
| Dec 31, 2024 | -224,000.00 |
| Sep 30, 2024 | 19,000.00 |
| Jun 30, 2024 | 7.14 Mn |
| Mar 31, 2024 | -1.11 Mn |
| Dec 31, 2023 | -201,000.00 |
| Sep 30, 2023 | 442,000.00 |
| Jun 30, 2023 | -244,000.00 |
| Mar 31, 2023 | 40,000.00 |
| Dec 31, 2022 | 2.92 Mn |
| Sep 30, 2022 | 537,000.00 |
| Jun 30, 2022 | 9.06 Mn |
| Mar 31, 2022 | 56,000.00 |
| Dec 31, 2021 | 2.99 Mn |
| Sep 30, 2021 | 121,000.00 |